Drug delivery articles from across Nature Portfolio

A DNA origami nanodevice presents its hidden death ligand pattern in the acidic tumour microenvironment to kill cancerous cells, opening opportunities for effective and safe cancer therapy.

Photobleaching-harnessing charge conversion initiates nanomedicine transcytosis, improving therapeutic outcomes in various rectal tumour mouse models.

The authors propose a framework to be followed during preclinical investigation of nanomedicines to increase their translatability potential.

Mitochondria disruption can elicit immune responses. Here the authors report the design and characterization of mitochondria targeting drug-free nanoassemblies promoting immunogenic cell death and anti-tumor immune responses in preclinical models.

Generic chemical approaches that can universally modulate photodynamic reactivity in organic photosensitizers are of high interest. Here, the authors present a strategy to fine-tune the production of singlet oxygen in multiple photosensitive scaffolds under the activation of bioresponsive and bioorthogonal stimuli.

Co-delivery of TLR7/8 agonists and TGF-β inhibitors (TGFβi) has the potential to overcome immunosuppression in the tumor microenvironment. Here the authors describe the application of the CarboCell technology for the sustained intratumoral release of a TLR7/8 agonist alone or in combination with a TGFβi, promoting anti-tumor immune responses in preclinical cancer models.

A DNA origami nanodevice presents its hidden death ligand pattern in the acidic tumour microenvironment to kill cancerous cells, opening opportunities for effective and safe cancer therapy.

Photobleaching-harnessing charge conversion initiates nanomedicine transcytosis, improving therapeutic outcomes in various rectal tumour mouse models.

We have developed a versatile approach for promoting the penetration of commensal bacteria into the intestinal mucosa, by coating the bacterial surface with poly(ethylene glycol) (PEG). PEGylation-enabled penetration facilitated the preferential localization of bacteria at the mucus layer of the intestinal mucosal barrier, thereby reinforcing this barrier.

The oral delivery of difficult-to-drug molecules, such as peptides, can be achieved using milk-derived extracellular vesicles. The Tiny Cargo Company has established a workflow for the large-scale production of extracellular vesicles from milk for the development of XoLacta — an oral therapy that mitigates the side effects of radiation therapy.

An article in Science Robotics reports green algae-based microrobots, carrying macrophage membrane-coated nanoparticles, that can be orally administered to neutralize proinflammatory cytokines in the gastrointestinal tract to treat inflammatory bowel disease.